ClinicalTrials.Veeva

Menu

The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease (CCHD)

P

Pediatrix

Status

Completed

Conditions

Congenital Heart Disease

Study type

Observational

Funder types

Other

Identifiers

NCT01749059
PDX-003-11

Details and patient eligibility

About

The purpose of this study is to evaluate the impact of implementing a universal pulse oximeter screening as a way to detect critical congenital heart disease in otherwise well-appearing newborns.

Enrollment

6,147 patients

Sex

All

Ages

Under 30 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Documentation of informed consent and authorization.
  2. Full term and late preterm newborns (EGA 35-44 weeks)
  3. On room air
  4. Neonates known to have a congenital heart defect at the time of screening, e.g., antenatal diagnosis or diagnosis within the first 24 hours after birth
  5. Parents agree to follow-up contact post discharge

Exclusion criteria

  1. On supplemental oxygen
  2. Admitted to the Neonatal Intensive Care Unit
  3. Parents do not agree to follow-up
  4. Greater than 30 days of age

Trial design

6,147 participants in 1 patient group

Congenital Heart Defect

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems